Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...
The non-binding MOU seeks to explore opportunities to ensure sustainable access for patients in Saudi Arabia to critical ...
Irish Examiner on MSN
MSD beats revenue expectations amid pivot to new drugs
MSD beat third-quarter sales expectations on strong results from its pneumonia vaccine as the company works to find new growth drivers ahead of the upcoming patent loss for its star drug Keytruda.The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback